The New England Journal of Medicine June 24, 2021

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Andrew N.J. Tutt et al.

Bottom Line

In patients with high-risk, HER2-negative early breast cancer and germline BRCA1/2 mutations, 1 year of adjuvant olaparib significantly improved invasive and distant disease-free survival compared to placebo.

Key Findings

1. Olaparib significantly improved 3-year invasive disease-free survival (IDFS) to 85.9% compared to 77.1% with placebo (HR 0.58; 99.5% CI, 0.41 to 0.82; P<0.001) [1.1.9].
2. 3-year distant disease-free survival (DDFS) was significantly higher in the olaparib group (87.5%) compared to the placebo group (80.4%) (HR 0.57; 99.5% CI, 0.39 to 0.83; P<0.001).
3. At the interim analysis, 3-year overall survival was 92.0% with olaparib and 88.3% with placebo (HR 0.68; 99% CI, 0.44 to 1.05; P=0.02), which did not cross the prespecified boundary for statistical significance (P<0.01).
4. Grade 3 or higher adverse events were more common with olaparib, including anemia (8.7%) and neutropenia (4.8%), leading to treatment discontinuation in 9.9% of patients compared to 4.2% in the placebo group.

Study Design

Design
RCT
Double-Blind
Sample
1,836
Patients
Duration
2.5 yr
Median
Setting
Multicenter, multinational
Population Patients with HER2-negative early breast cancer, germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants, and high risk of recurrence despite local treatment and neoadjuvant or adjuvant chemotherapy.
Intervention Olaparib (300 mg twice daily) for 1 year.
Comparator Placebo (twice daily) for 1 year.
Outcome Invasive disease-free survival (IDFS).

Study Limitations

Short median follow-up (2.5 years) at the time of this primary event-driven interim analysis [1.1.9].
Overall survival data did not meet the strict prespecified alpha boundary for significance at this initial interim analysis (though later long-term updates confirmed an OS benefit).
The trial focused strictly on a high-risk patient population, leaving the efficacy of adjuvant olaparib in lower-risk BRCA-mutated breast cancers unclear.
Significant rates of adverse events (especially anemia and fatigue) required frequent dose interruptions or modifications.

Clinical Significance

The OlympiA trial established 1 year of adjuvant olaparib as a standard of care for patients with high-risk, HER2-negative, germline BRCA1/2-mutated early breast cancer. This finding fundamentally changed practice by mandating early germline genetic testing in the breast cancer diagnostic pathway to identify candidates for targeted, curative-intent adjuvant PARP inhibition.

Historical Context

Prior to OlympiA, PARP inhibitors like olaparib were established as effective targeted therapies for metastatic gBRCA-mutated breast cancer (demonstrated by the OlympiAD trial) and advanced ovarian cancer. OlympiA represented a paradigm shift in precision oncology by moving PARP inhibitors into the adjuvant setting, proving that exploiting homologous recombination repair deficiency via synthetic lethality could effectively prevent recurrence and progression to metastatic disease in early-stage breast cancer.

Guided Discussion

High-yield insights from every perspective

Med Student
Medical Student

How does the mechanism of action of olaparib specifically target breast cancer cells with germline BRCA1 or BRCA2 mutations while sparing normal cells?

Key Response

Olaparib is a PARP inhibitor. PARP enzymes repair single-strand DNA breaks. Inhibiting PARP leads to double-strand breaks during cell replication. Normal cells repair these via homologous recombination (HR), but BRCA1/2-mutated cells are HR-deficient. This results in cell death through a concept known as synthetic lethality.

Resident
Resident

Based on the OlympiA trial criteria, which specific high-risk clinical and pathologic features in early-stage HER2-negative breast cancer with a germline BRCA mutation warrant the addition of 1 year of adjuvant olaparib?

Key Response

For triple-negative disease, it requires non-pCR after neoadjuvant chemo, or at least pT2 or pN1 if adjuvant chemo was used. For hormone receptor-positive disease, it requires non-pCR and a CPS+EG score of 3 or greater, or at least 4 positive lymph nodes if adjuvant chemo was used. Recognizing these criteria is essential for appropriately prescribing this therapy.

Fellow
Fellow

How does the concurrent use of endocrine therapy in the HR-positive subgroup of the OlympiA trial influence our understanding of resistance, and how should we sequence olaparib with CDK4/6 inhibitors in this high-risk population?

Key Response

The OlympiA trial allowed concurrent endocrine therapy but did not include CDK4/6 inhibitors, which are standard for high-risk HR-positive disease based on the monarchE trial. Fellows must navigate the data vacuum regarding overlapping toxicities, optimal sequencing, and whether PARP or CDK4/6 inhibition takes precedence in a gBRCA-mutated, HR-positive, node-positive patient.

Attending
Attending

Given the definitive overall survival benefit seen in updated OlympiA analyses, how does this mandate a paradigm shift in the timing and universal accessibility of germline genetic testing for newly diagnosed early-stage breast cancer patients?

Key Response

Traditionally, genetic testing was prognostic or used for surgical decision-making. The OlympiA data fundamentally shifted genetic testing to a purely therapeutic imperative, meaning delays in systemic testing directly deny a life-saving adjuvant therapy. This requires systematic restructuring of multidisciplinary intake to ensure rapid turnaround testing.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD
PhD

The OlympiA trial utilized a hierarchical testing strategy for its endpoints. What are the statistical advantages of this alpha-spending approach in an event-driven trial, and how does it protect against Type I error inflation compared to co-primary endpoints?

Key Response

Hierarchical testing ensures strict control of the family-wise error rate by only formally testing a subsequent endpoint if the previous one crosses the pre-specified significance boundary. In event-driven oncology trials where early readout of surrogates occurs before overall survival, this preserves statistical power and strictly limits Type I error while allowing interim analyses.

Journal Editor
Journal Editor

In assessing the generalizability of the OlympiA trial, how does the variable use and completion of prior platinum-based neoadjuvant chemotherapy among the study cohorts introduce potential selection bias regarding the true efficacy of adjuvant olaparib?

Key Response

A tough reviewer would flag that prior platinum exposure can select for BRCA-reversion mutations or primary resistance. If the platinum-pretreated group had disproportionate non-pCR and then received olaparib, their baseline resistance mechanisms might artificially alter the perceived efficacy of PARP inhibition, an important stratification factor to scrutinize.

Guideline Committee
Guideline Committee

How does the OlympiA trial compel an update to ASCO and NCCN guidelines regarding the integration of adjuvant olaparib, and how does it define algorithmic pathways when competing with other adjuvant therapies like capecitabine or abemaciclib?

Key Response

OlympiA provides Level I evidence that fundamentally changed NCCN guidelines, yielding a Category 1 recommendation for 1 year of adjuvant olaparib in high-risk gBRCAm HER2-negative breast cancer. The committee must specifically operationalize the rules for sequencing, defining precisely how it supersedes or sequences with capecitabine for TNBC or abemaciclib for HR-positive disease to establish clear guidelines.

Clinical Landscape

Noteworthy Related Trials

2017

OlympiAD Trial

n = 302 · NEJM

Tested

Olaparib 300 mg twice daily

Population

Patients with HER2-negative metastatic breast cancer and a germline BRCA mutation

Comparator

Standard chemotherapy

Endpoint

Progression-free survival

Key result: Olaparib significantly prolonged progression-free survival compared to standard chemotherapy (median 7.0 vs 4.2 months).
2017

CREATE-X Trial

n = 910 · NEJM

Tested

Adjuvant capecitabine

Population

HER2-negative early breast cancer patients with residual invasive disease after neoadjuvant chemotherapy

Comparator

Standard care

Endpoint

Disease-free survival

Key result: Adjuvant capecitabine significantly prolonged disease-free and overall survival among patients with HER2-negative breast cancer who had residual disease post-neoadjuvant therapy.
2018

EMBRACA Trial

n = 431 · NEJM

Tested

Talazoparib 1 mg daily

Population

Patients with advanced breast cancer and a germline BRCA1/2 mutation

Comparator

Standard chemotherapy

Endpoint

Progression-free survival

Key result: Talazoparib provided a significant progression-free survival benefit over standard chemotherapy (median 8.6 vs 5.6 months).

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis